Cocaine

• 1. Introduction

  ›

  Cocaine is a substance that has shaped empires, fueled cartels, redrawn borders, and rewired human brains, all while originating from the leaves of two plants growing on Andean hillsides. Indigenous South Americans have been chewing those leaves for at least 8,000 years. Yet in 2023, the number of people using cocaine worldwide reached 25 million, up from 17 million a decade earlier, making it the fastest-growing illicit drug market on the planet. How did a plant remedy traded in the high Andes become a global crisis? What does cocaine actually do inside the brain, and why is it so hard to stop? And who profits from the trail between a Bolivian hillside and a European city? Those are the threads this documentary follows.

• 2. The Andean Root

  ›

  Coca leaves were not just a casual stimulant for Andean civilizations. In the ancient Wari culture, in the Inca empire, and among their modern indigenous descendants, the leaf was woven into daily survival. People chewed it against hunger, cold, and altitude sickness. The traditional method involved tucking a wad of leaves against the inner cheek alongside burnt alkaline ash, letting the juices seep slowly through the mucous membrane.

  When Spanish colonizers arrived in South America, their first instinct was to ban the plant. That ban did not last. Once the Spanish realized how central coca was to the labor of indigenous workers in mines and fields, they reversed course, legalized the leaf, and taxed it. The commercial logic of the plant was already visible centuries before laboratories isolated its active compound.

  Friedrich Gaedcke first isolated the active ingredient in 1855. Albert Niemann later refined that work and gave the compound its name. By the late nineteenth century, cocaine had spread into Western medicine as a local anesthetic, into patent remedies, and into widely sold drinks. Karl Koller's discovery of cocaine's use as a local anesthetic is regarded as the second most significant advance in the entire history of anesthesia. That reputation would not last intact.

• 3. How It Works in the Brain

  ›

  Cocaine acts on the brain by blocking the dopamine transporter, a protein whose normal job is to vacuum up dopamine after a neuron fires and return it to storage. When cocaine binds tightly to that transporter, dopamine accumulates in the synaptic cleft. The flood of dopamine activates reward receptors and produces the euphoria that makes the drug feel worth repeating.

  But dopamine is only part of the picture. Cocaine is classified pharmacologically as a serotonin-norepinephrine-dopamine reuptake inhibitor, meaning it simultaneously slows the recycling of three major neurotransmitters. Scientists studying the ratios found that cocaine inhibits serotonin and norepinephrine reuptake at roughly 2:3 and 2:5 ratios relative to dopamine respectively.

  Research has also complicated the simple reuptake story. To produce euphoria through intravenous administration, a dose of 0.3 to 0.6 milligrams per kilogram of body weight is needed, which blocks roughly 66 to 70 percent of the dopamine transporter in the brain. Beyond that threshold, re-administering cocaine does not significantly increase transporter blockade, yet euphoria continues to rise. This discrepancy is not observed with other dopamine reuptake inhibitors and has led some researchers to propose that cocaine may also function as a negative allosteric modifier of the dopamine transporter, producing a kind of release rather than just a blockade. The full mechanism is still under investigation.

  Cocaine also blocks sodium channels in neurons, which is the basis of its entirely separate and legitimate use as a local anesthetic.

• 4. The Body Under Siege

  ›

  Snorting cocaine produces maximum physiological effects within 40 minutes and maximum psychotropic effects within 20 minutes. Those effects last roughly 60 to 90 minutes via insufflation, while the drug itself has a biological half-life of only 0.7 to 1.5 hours. The brevity of the high drives repeated dosing, and repeated dosing is where the body begins to suffer.

  Acutely, cocaine constricts blood vessels, drives up heart rate and blood pressure, elevates body temperature, and surges cortisol from the adrenal gland. These effects can escalate to atrial fibrillation, ventricular tachycardia, angina, or full cardiac arrest. According to the European Union Drugs Agency, the estimated minimum lethal dose is 1.2 grams, but sensitive individuals have died from as little as 30 milligrams applied to mucous membranes, which is 40 times below that threshold. At the other extreme, long-term users have tolerated doses as high as 5 grams per day.

  Chronic use layers additional damage. Brain imaging studies consistently show structural and functional abnormalities in people who misuse cocaine compared to non-users. The drug reduces cerebral blood flow, damages gray matter in regions tied to memory, attention, and emotion, and disrupts dopamine signaling in ways that appear to accelerate brain aging. A 2014 study found that increased cocaine use correlates with greater impairment in working memory, though reduced use or abstinence can lead to partial or full recovery, particularly for those who began using later in life.

  Mixing cocaine with alcohol creates a third substance the body never signed up for: cocaethylene. This unique metabolite forms only when both substances are present simultaneously and is associated with an 18 to 25-fold increased risk of sudden death compared to cocaine use alone.

• 5. Addiction and the Changing Brain

  ›

  Cocaine can induce tolerance after a single dose. Repeated use frequently produces full addiction, with the brain's architecture shifting to sustain drug-seeking behavior. A key molecular mechanism involves the overexpression of a protein called delta FosB in the nucleus accumbens, a region central to reward processing. Each dose of cocaine raises delta FosB levels without any known ceiling.

  Elevated delta FosB triggers a chain reaction: it raises levels of brain-derived neurotrophic factor, which promotes new dendritic growth and denser spine connections in neurons of the nucleus accumbens and prefrontal cortex. In transgenic mice engineered to express high levels of delta FosB in these areas, researchers observed heightened behavioral sensitization to cocaine, self-administration of cocaine at lower doses, and greater propensity to relapse after withdrawal.

  Cocaine also leaves marks on DNA. Studies in rodents show increased DNA damage in brain cells after cocaine use, and during subsequent repair, epigenetic changes accumulate, modifications to the chromatin structure through methylation and acetylation. These are described as persistent epigenetic scars that may underlie the long-term changes seen in cocaine addiction.

  Withdrawal symptoms fall into two clusters: depressive symptoms such as depression, craving, and insomnia, and somatic symptoms such as increased appetite and fatigue. Depressive symptoms are linked to worse long-term outcomes including longer depressive episodes, longer treatment duration, and riskier behaviors. About 25 percent of adults with attention deficit hyperactivity disorder use cocaine at some point, and 10 percent develop a cocaine use disorder during their lifetime.

  No medication currently carries regulatory approval for cocaine use disorder. Cocaine Anonymous, a twelve-step program founded on the 18th of November 1982 and modeled closely on Alcoholics Anonymous, remains one of the primary organized recovery pathways.

• 6. The Global Supply Chain

  ›

  Coca cultivation is concentrated in the Andes regions of Bolivia, Peru, and Colombia, and is now expanding into Central America, including Honduras, Guatemala, and Belize. In Peru, legal coca cultivation is managed by a state company called the National Coca Company, yet approximately 90 percent of coca leaves produced in Peru are diverted to illegal actors for cocaine manufacturing.

  The cocaine boom, a sharp rise in illegal production and trafficking, began in the late 1970s and peaked in the 1980s. Since that era, the trade's structure has transformed. Through the 1980s and into the early 2000s, centralized and hierarchical cartels such as the Medellin and Cali operations dominated the market. By the early 2000s, that model fragmented into a diverse network of global trafficking links. South American cocaine now reaches Europe, Africa, Asia, and Oceania through multiple competing routes.

  Seizures rose by 68 percent from 2019 to 2023, according to the UNODC World Drug Report 2025, yet the CCDB, a U.S. government dataset involving 26 agencies and 20 foreign partners, found that despite large seizures, interdiction captures only a small fraction of total trafficking events and has minimal impact on cocaine prices in the United States.

  The environmental cost of this production is extensive. Between 2001 and 2004, the UNODC estimated that 97,622 hectares of primary forest were cleared for coca cultivation in the Andean region alone. Clandestine farming involves unregulated, highly toxic pesticides whose effects travel up the food chain. By 2015, Colombia had announced a ban on aerial glyphosate spraying used in eradication programs, partly in response to documented health complaints including rashes, fever, diarrhoea, and eye infections in affected communities.

• 7. Adulteration and Emerging Research

  ›

  Street cocaine is rarely pure. Between 2009 and 2016, studies showed that 50 to 70 percent of all cocaine specimens worldwide contained levamisole. By October 2017, the US Drug Enforcement Administration reported that 87 percent of seized and analyzed cocaine bricks in the United States contained the substance. Inside the body, levamisole converts into aminorex, a stimulant with amphetamine-like effects and a long duration of action. It is also associated with serious autoimmune syndromes. Fentanyl and local anesthetics are among other common adulterants.

  Researchers have been pursuing a vaccine approach to addiction treatment. Calix coca is an experimental vaccine in development since 2015 at the Federal University of Minas Gerais in Brazil. A separate vaccine, TA-CD, developed by the Xenova Group, combines norcocaine with inactivated cholera toxin; it is designed to prompt the immune system to produce antibodies that bind cocaine in the bloodstream before it can reach the brain.

  A study conducted in Lima, Peru, found that using coca leaf infusion alongside counseling reduced relapse rates and significantly increased the duration of abstinence among individuals in treatment for cocaine dependence, suggesting the same plant at the source of cocaine may have a role in addressing the addiction it helped create. In 2022, researchers discovered that a genetically modified version of Nicotiana benthamiana was able to produce 25 percent of the cocaine concentration found in a natural coca plant, though separating that cocaine from the plant's native nicotine and related alkaloids remains a significant obstacle.